Evidence Level:Sensitive: D – Preclinical
Title:
A Cell Surface-Binding Antibody Atlas Nominates a MUC18-Directed Antibody-Drug Conjugate for Targeting Melanoma
Excerpt:AMT-253 was also efficacious in a wide range of MUC18-expressing solid tumors.
DOI:10.1158/0008-5472.CAN-23-1356